BioNTech SE ADR (BNTX) News
Filter BNTX News Items
BNTX News Results
|Loading, please wait...|
BNTX News Highlights
- BNTX's 30 day story count now stands at 51.
- Over the past 23 days, the trend for BNTX's stories per day has been choppy and unclear. It has oscillated between 1 and 14.
- BA, MRNA and SE are the most mentioned tickers in articles about BNTX.
Latest BNTX News From Around the Web
Below are the latest news stories about BIONTECH SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.
Volatility ticked up on Monday, with the broader indices falling more than 1% on news of the protests at the Foxconn factory Zhengzhou in China over the country’s draconian COVID-19 rules.
In this article, we will discuss the 12 best falling stocks to buy now. If you want to explore similar stocks, you can read 5 Best Falling Stocks to Buy Now. We are approaching the end of the year which has been terrible for the markets. Fears of recession, the Ukraine war, supply chain woes, […]
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.
Companies that have strong quality, value, or growth grades are the stocks to buy once markets recognize their business potential.
PFE stock still remains a dirt-cheap dividend darling, even after across-the-board earnings beats and lifted guidance.
Novavax (NVAX) claims that GAVI's failure to procure its COVID vaccine doses is a reason to terminate the supply agreement. GAVI denies the company's claims and a legal battle is likely to follow.
In this piece, we will take a look at the 15 biggest European pharmaceutical companies. For more companies, head on over to 5 Biggest European Pharmaceutical Companies. Alongside the United States, Europe has some of the most advanced industries and economies in the world. While the Americans are rightly credited with having pioneered the modern […]
In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX - Research Report), with a price target of $148.00. The company's shares closed last Friday at $166.39.According to TipRanks, Fye is a 5-star analyst with an average return of 10.1% and a 53.51% success rate. Fye covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, BioMarin Pharmaceutical, and Emergent Biosolutions.Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $203.88, implying a 22.53% upside from current levels.
Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages.